Abstract: The present invention relates to recombinant DNA encoding the AcuI restriction endonuclease as well as AcuI methylase, and expression of AcuI restriction endonuclease and AcuI methylase in E. coli cells containing the recombinant DNA.
Type:
Grant
Filed:
April 16, 2003
Date of Patent:
March 14, 2006
Assignee:
New England Biolabs, Inc.
Inventors:
James Samuelson, Shuang-yong Xu, Diana O'Loane
Abstract: The present invention provides methods that utilize compositions containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.
Abstract: Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein.
Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
Type:
Application
Filed:
September 26, 2005
Publication date:
February 9, 2006
Applicant:
New England Biolabs, Inc.
Inventors:
Ming-Qun Xu, Sebastien Ferrandon, Christopher Taron, Paul Colussi
Abstract: Methods are described for detecting genes that encode toxic proteins using maps derived from shotgun libraries by determining the presence of gaps in clone start sites on either side of open reading frames. The method is exemplified by identifying a previously unknown restriction endonuclease gene.
Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
Abstract: The present invention relates to: recombinant DNA encoding the SbfI restriction endonuclease as well as the SbfI methylase, and expression of the SbfI restriction endonuclease and SbfI methylase in E. coli cells containing the recombinant DNA; and methods for cloning the SbfI restriction gene (sbfIR) from Streptomyces species Bf-61 into E. coli by PCR. The method relied on primers based on DNA sequences predicted from amino acid sequences of the purified SbfI restriction endonuclease.
Type:
Grant
Filed:
September 22, 2003
Date of Patent:
October 25, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Keith D. Lunnen, Theodore Davis, Geoffrey G. Wilson
Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
Abstract: A method for cloning restriction-modification system is provided whereby the target modification methylase is produced and confers full protection during all growth phases in which the cognate restriction enzyme is present. The method is employed in the cloning of the MseI restriction-modification system.
Type:
Application
Filed:
December 21, 2004
Publication date:
July 21, 2005
Applicant:
New England Biolabs, Inc.
Inventors:
Romualdas Vaisvila, Richard Morgan, Rebecca Kucera, Elisabeth Raleigh
Abstract: Methods are provided for engineering novel strand-specific nicking endonucleases by means of an in vivo enrichment of a plasmid library containing a randomly mutagenized restriction endonuclease gene. The plasmids contain adjacent to the gene a cleavable or nickable sequence for cleaving or nicking by the endonuclease product of the gene and a second recognition site for a second endonuclease. The plasmid library is used to transform unmodified host cells. Plasmids from the cultured transformed cells may be analyzed by an in vitro assay for nicking and the nicked plasmids pooled and used to transform host cells. The product is then pooled and the single-stranded specificity of the endonuclease is then determined. The product is either cloned after amplification or identified by use of a selectable marker.
Abstract: The present invention relates to recombinant DNA which encodes the Tth111II restriction endonuclease-methylase fusion protein (Tth111IIRM), expression of Tth111II restriction endonuclease-methylase fusion protein in E. coli cells containing the recombinant DNA, and purification of Tth111II endonuclease-methylase fusion protein to near homogeneity.
Type:
Grant
Filed:
January 8, 2003
Date of Patent:
July 19, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Zhenyu Zhu, Derek Robinson, Jack Benner, Shuang-yong Xu
Abstract: Methods are provided for identifying novel strand-specific nicking endonucleases by means of in vitro backcrosses of mutagenized restriction endonuclease genes with their wild-type counterpart and identifying the resulting nicking endonucleases by their cleavage activity and their strand specificity. Examples of nicking endonucleases identified by this method include Nt.Bsa I and Nb.BsaI, Nt.BsmAI and Nb.BsmAI and Nt.BsmBI.
Abstract: A method is provided for identifying a restriction endonuclease, which includes the steps of (a) screening a target DNA sequence for the presence of known methylase sequence motifs, (b) identifying any open reading frames which lie close to the methylase sequence motifs screened in step (a), and (c) assaying the protein products of these open reading frames for restriction endonuclease activity. Methods for identifying isoschizomers of known restriction endonucleases, which isoschizomers possess a desired physical property, such as thermostability, are also provided by the present invention, as are several novel restriction endonucleases isolated from M. jannaschii, MjaIII and MjaIV. Additionally, a gene was identified that encoded a previously observed endonuclease activity, designated MjaII. Also provided by the present invention are vectors suitable for cloning a DNA sequence encoding a cytotoxic protein, via independent transcription promotors which may be selectively controlled by several conditions.
Type:
Grant
Filed:
July 30, 2002
Date of Patent:
June 14, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Richard J. Roberts, Devon R. Byrd, Richard D. Morgan, Jay Patti, Christopher J. Noren
Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
Type:
Grant
Filed:
February 26, 2003
Date of Patent:
May 24, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Ming-Qun Xu, Sebastien M. Ferrandon, Christopher H. Taron, Paul A. Colussi
Abstract: The present invention relates to recombinant DNA encoding the BsrGI restriction endonuclease as well as BsrGI methyltransferase, expression of BsrGI restriction endonuclease and BsrGI methyltransferase in E. coli cells containing the recombinant DNA.
Abstract: A new type of transgene system is disclosed which allows efficient protein expression in a target host such as a plant, but avoids the undesirable result of the migration of the transgene into related host system and/or to the environment via the pollen. The methods described herein may also be applied to the expression of virtually any protein of interest (e.g. a toxic protein) in eukaryotic (yeast, insect, mammalian cells, etc.) and prokaryotic (E. coli, etc.) organisms.
Type:
Grant
Filed:
May 23, 2000
Date of Patent:
February 22, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Ming-Qun Xu, Thomas C. Evans, Sriharsa Pradhan, Donald G. Comb, Henry Paulus, Luo Sun, Lixin Chen, Inca Ghosh
Abstract: A method for the ligation of expressed proteins which utilizes inteins, for example the RIR1 intein from Methanobacterium thermotrophicum, is provided. Constructs of the Mth RIR1 intein in which either the C-terminal asparagine or N-terminal cysteine of the intein are replaced with alanine enable the facile isolation of a protein with a specified N-terminal, for example, cysteine for use in the fusion of two or more expressed proteins. The method involves the steps of generating a C-terminal thioester-tagged target protein and a second target protein having a specified N-terminal via inteins, such as the modified Mth RIR1 intein, and ligating these proteins. A similar method for producing a cyclic or polymerized protein is provided. Modified inteins engineered to cleave at their C-terminus or N-terminus, respectively, and DNA and plasmids encoding these modified inteins are also provided.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
February 1, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Thomas C. Evans, Ming-Qun Xu, Shaorong Chong
Abstract: A method for cloning restriction-modification system is provided whereby the target modification methylase is produced and confers full protection during all growth phases in which the cognate restriction enzyme is present. The method is employed in the cloning of the MseI restriction-modification system.
Type:
Grant
Filed:
October 12, 2000
Date of Patent:
January 25, 2005
Assignee:
New England Biolabs, Inc.
Inventors:
Romualdas Vaisvila, Richard D. Morgan, Rebecca B. Kucera, Toby E. Claus, Elisabeth A. Raleigh